Krystal Biotech, Inc. (KRYS) P/E Ratio History
UndervaluedTrading at 50.9x vs 5Y avg 202.0x · 60th percentile · Below historical baseline · Data 2023–2026
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, Krystal Biotech, Inc. (KRYS) trades at a price-to-earnings ratio of 50.9x, with a stock price of $348.06 and trailing twelve-month earnings per share of $7.38.
The current P/E is 75% below its 5-year average of 202.0x. Over the past five years, KRYS's P/E has ranged from a low of 26.5x to a high of 1550.8x, placing the current valuation at the 60th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, KRYS trades at a 130% premium to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, KRYS commands a significant premium over the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our KRYS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
KRYS Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
KRYS P/E vs Peers
Cell and Gene Therapy Developers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 9.4Lowest | -Best | +68% | |
| $7B | 10.2 | -Best | +264%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
KRYS Historical P/E Data (2023–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $258.32 | $7.48 | 34.5x | -83% |
| FY2025 Q4 | Dec 31 2025 | $246.54 | $6.85 | 36.0x | -82% |
| FY2025 Q3 | - | $176.53 | $6.67 | 26.5x | -87% |
| FY2025 Q2 | Jun 30 2025 | $137.46 | $4.92 | 27.9x | -86% |
| FY2025 Q1 | Mar 31 2025 | $180.30 | $4.16 | 43.3x | -79% |
| FY2024 Q4 | - | $156.66 | $2.99 | 52.4x | -74% |
| FY2024 Q3 | Sep 30 2024 | $182.03 | $1.77 | 102.8x | -49% |
| FY2024 Q2 | Jun 30 2024 | $183.64 | $3.65 | 50.3x | -75% |
| FY2024 Q1 | Mar 31 2024 | $177.93 | $1.87 | 95.1x | -53% |
| FY2023 Q4 | Dec 31 2023 | $124.06 | $0.08 | 1550.8x | +668% |
Average P/E for displayed period: 202.0x
Full Stock Analysis
Deep dive into KRYS consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
3+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
KRYS — Frequently Asked Questions
Quick answers to the most common questions about buying KRYS stock.
What is KRYS's P/E ratio?
Krystal Biotech, Inc. (KRYS) trailing twelve-month P/E ratio is 50.9x, based on TTM diluted EPS of $7.38. The 5-year average P/E is 202.0x and the historical range spans 26.5x to 1550.8x.
Is KRYS stock overvalued or undervalued?
KRYS trades at 50.9x P/E, below its 5-year average of 202.0x. At the 60th percentile of its historical range (26.5x–1550.8x), the stock is priced at a discount to its own history.
Is KRYS stock expensive?
No, KRYS is not expensive on a historical basis. The current P/E of 50.9x is below the 5-year average of 202.0x and sits at the 60th percentile of its valuation range.
What is KRYS's historical P/E range?
Over the past 5 years, KRYS's P/E ratio has ranged from 26.5x to 1550.8x, with a median of 50.3x and an average of 202.0x. The current P/E of 50.9x places the stock at the 60th percentile of this range. Full historical data spans 2023–2026.
How does KRYS's P/E compare to the S&P 500?
KRYS trades at 50.9x P/E versus the S&P 500 median of 24.4x. The 109% premium to the market typically reflects higher expected earnings growth or quality.
How does KRYS's valuation compare to Healthcare peers?
Krystal Biotech, Inc. P/E of 50.9x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is KRYS's PEG ratio?
KRYS PEG ratio is N/A, based on a P/E of 50.9x and EPS growth of 128.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is KRYS's earnings yield?
KRYS earnings yield is 1.97%, the inverse of its 50.9x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.